Introduction {#sec1}
============

The genetic basis of common diseases continues to be a subject of significant interest in human genetics research in the post-genome era. Genome-wide association studies (GWAS) have been successful in uncovering hundreds of common genetic variants associated with multiple complex traits ([@ref1]). Despite representing a major advance in deciphering genetic structure of complex diseases, GWAS have faced two major setbacks. First, the associated variants often reside in non-coding regions of the genome, representing a tag SNP (single nucleotide polymorphism) for the causal variant(s). Thus, the causal gene(s) and genetic variant(s) are not immediately evident for a majority of identified loci. Second, barring few exceptions, the associated variants identified by GWAS explain only a small proportion of the disease heritability ([@ref2]). These observations have led to shifts in paradigms including possible involvement of rare variants in complex traits. In fact, both common and rare variants have been recognized to contribute to the genetic architecture of multifactorial diseases ([@ref3]). Nevertheless, common variants have long been central to these investigations, primarily because of the identification of millions of SNPs across the genome that could be genotyped in a high-throughput manner ([@ref4],[@ref5]). The advent of next-generation sequencing technologies and reduced cost of sequencing have prompted a new wave of studies for evaluating the impact of rare and low-frequency variants in complex diseases ([@ref6]).

Age-related macular degeneration (AMD; MIM, 603075) is a late-onset multifactorial, neurodegenerative disease, which affects the macular region of the retina, eventually resulting in the loss of central vision. AMD afflicts 8.7% of the worldwide population ([@ref7]) with over 10 million individuals in the United States alone, posing a substantial healthcare burden ([@ref8]). The clinical presentation of the disease is progressive and can be broadly divided into early, intermediate and late (advanced) stage ([@ref9]). Early and intermediate stages are mostly asymptomatic and characterized by changes in the retinal pigment epithelium (RPE) and accumulation of extracellular aggregates, called drusen. Central vision loss characterizes the advanced stage, which can be further subdivided into two forms: geographic atrophy (GA) and choroidal neovascularization (CNV) ([@ref10]). Therapeutic interventions are available for many patients with CNV, which represents a small proportion of all AMD cases ([@ref11]).

AMD is a complex trait determined by a combination of advanced age, genetic variants and environmental factors such as smoking and nutrition ([@ref12],[@ref13]). Genetic studies in AMD have contributed significantly to biological underpinnings of its pathogenesis ([@ref14],[@ref15]). The most recent GWAS of 16,144 patients and 17,832 control individuals identified 52 independently associated variants at 34 loci that explain over 50% of the genomic heritability ([@ref16]). These findings have highlighted the complement system, extracellular matrix remodeling and lipid metabolism in AMD pathogenesis. Rare variants are also suggested to contribute to the heritability in AMD ([@ref16],[@ref17]). Targeted sequencing of candidate genes and whole exome sequencing (WES) have identified rare coding variants in the *CFH*, *C3*, *CFI*, *C9*, *CFB* and *COL8A1* genes at GWAS loci ([@ref18]). Additional studies have established an unequivocal role of the complement system in AMD pathology ([@ref25]). At this stage, the contribution of rare variants outside of the GWAS loci remains largely unexplored due to power issues, as case-control designs require sequencing of large numbers of samples to achieve statistical significance.

Early investigations indicating the aggregation of AMD in families strongly indicated a strong genetic contribution ([@ref31]), and such families can serve as a reference for identifying rare variants and causal genes. Linkage analysis in AMD families had initially led to the identification of the 1q31 and 10q26 loci ([@ref35]), which were later identified as the top two association signals in GWAS and/or by candidate gene association at the *CFH* ([@ref39]) and *ARMS2*-*HTRA1* ([@ref44]) loci, respectively. In addition, exome sequencing in large, multiplex families identified a rare variant in the *FBN2* gene ([@ref47]) in the early form of macular degeneration and confirmed the occurrence of rare variants in the *CFH*, *CFI*, *C9* and *C3* genes at multiple AMD loci ([@ref21],[@ref28],[@ref29],[@ref48]). Thus, AMD families can provide new insights into AMD by identifying additional rare variants and pointing to candidate causal genes.

In this study, we performed WES of 264 individuals from 63 multiplex families. To determine causality of genes in loci previously identified by GWAS, we analyzed these families for rare protein-altering variants in coding regions at AMD-associated loci. In addition, we examined whole exome data for rare coding variants outside the AMD-associated loci to identify new AMD candidate genes.

Results {#sec2}
=======

Whole exome sequencing in AMD families {#sec3}
--------------------------------------

We assembled a cohort of 226 affected and 38 unaffected individuals from 63 multiplex families with a history of AMD ([Table 1](#TB1){ref-type="table"}). A majority of the cohort (51.5%) had advanced stages of the disease (GA, CNV or GA + CNV) with a mean age of 78.2 years. Individuals with early and intermediate stages had a mean age of 69.1 years and constituted 34% of the affected individuals ([Table 1](#TB1){ref-type="table"}). We also included 38 unaffected members (age \> 55 years) from 32 families with a mean age of 72.1 years. Exome capture and sequencing was performed at two different centers \[at the National Eye Institute (NEI) for the NEI families and at ErasmusMC Rotterdam for the Radboudumc families\] ([Fig. 1](#f1){ref-type="fig"}). As the WES data were captured on different platforms, we extracted variants from the shared 58.55 Mb exome regions. WES data were analyzed following the guidelines of GATK best practices ([Fig. 1](#f1){ref-type="fig"}), resulting in the identification of 107,348 coding variants ([@ref53]). We identified 4957 variants after additional, multi-tiered filtering based on quality, allele depth, minor allele frequency (MAF) in matched controls and predicted effect of the variants ([Fig. 1](#f1){ref-type="fig"}). The variants segregating in a family were considered only if the variant was shared among 80% or more affected family members and/or segregated in all but one affected individual. We excluded the variants that were present in available unaffected member(s) of the respective family.

###### 

Overview of families analyzed

                                                         Radboudumc cohort   NEI cohort
  ------------------------------------------------------ ------------------- ------------
  Number of families                                     44                  19
  Total number of individuals                            195                 69
  Males, females                                         73,122              30, 39
  Number of individuals with advanced AMD                82                  54
  Mean age for advanced AMD                              76.5                80.8
  Number of individuals with early or intermediate AMD   82                  8
  Mean age for early or intermediate AMD                 68.5                74.8
  Number of unaffected individuals                       31                  7
  Mean age of unaffected individuals                     70.8                77.5

![An overview of stepwise filtering of variants identified in multiplex AMD families using whole exome sequencing. We retained variants that were shared among 80% or more affected family members or segregated in all but one affected individual. Variants were discarded if they were present in one or more unaffected family members.](ddaa057f1){#f1}

Survey of rare coding variants in genes within GWAS loci {#sec4}
--------------------------------------------------------

We first analyzed the families for rare (MAF \< 1%) coding variants within 34 AMD-associated loci ([Table 2](#TB2){ref-type="table"}). The locus regions were defined by genome-wide significant variants and those within linkage disequilibrium (LD) (*r*^2^ \> 0.5), with an additional 500 kb to both sides, as described in the most recent AMD-GWAS study ([@ref16]). We identified 91 rare variants in 78 genes within the LD intervals of 29 known AMD loci and initially focused on loci where rare coding variants were identified in three or more families. Variants were detected in the *CFH*, *PUS7*, *RXFP2* and *PHF12* genes in three families and in the *TACC2* gene in four families ([Fig. 2A--D and F](#f2){ref-type="fig"}; [Table 2](#TB2){ref-type="table"}). We also included genes that were predicted as most likely candidates using the gene priority score (GPS), as described previously ([@ref16]). The scoring was based on expression of genes in AMD-relevant tissues (retina, RPE and choroid) and the presence of rare variants in AMD patients and their known biological functions. By combining our WES results with GPS score, we identified three additional likely AMD genes: *SPEF2* (PRLR-SPEF2 locus), *BCAR1* (CTRB2-CTRB1 locus) and *C9* (C9 locus) ([Table 2](#TB2){ref-type="table"}). Two independent non-synonymous variants (R201G and R421H) in *SPEF2* were predicted to be pathogenic and identified in two families ([Fig. 2G](#f2){ref-type="fig"}). No additional segregating rare variants were uncovered among the 16 genes within the LD region of the *PRLR*-*SPEF2* locus. A non-synonymous and splice variant in *BCAR1* is segregated in two families ([Fig. 2H](#f2){ref-type="fig"}). In addition, a single family with four affected members revealed the segregation of a rare, likely pathogenic variant P167S in *C9* ([Fig. 2D](#f2){ref-type="fig"}).

We next analyzed the expression of the eight genes where rare variants were identified in the retinal transcriptome and expression quantitative trait loci (eQTL) dataset that included both control and AMD donor samples ([@ref54]) ([Fig. 3](#f3){ref-type="fig"}). Six of these genes (*CFH*, *PUS7*, *PHF12*, *TACC2*, *SPEF2* and *BCAR1*) were expressed in the retina (counts per million, CPM \> 0), while no retinal expression was detected for *RXPF2* and *C9* ([Fig. 3A](#f3){ref-type="fig"}). Additionally, we evaluated gene expression changes during AMD progression by comparing the gene expression profile of the control retina with the profiles of the retina during early, intermediate and late stages of the disease. While we did not observe a significant difference \[at false discovery rate (FDR) ≤ 10%\] during disease progression, several candidates showed a trend of either increased or decreased expression ([Fig. 3B](#f3){ref-type="fig"}). We note that expression of four of the candidates (*PUS7*, *PHF12*, *SPEF2*, *BCAR1*) is regulated in the retina through common eQTL variants ([Fig. 3C](#f3){ref-type="fig"}).

###### 

Rare coding variants (MAF \< 1%) in genes within GWAS loci identified by WES

  Locus ([^a^](#tblfn1){ref-type="table-fn"}genes within LD ± 500 kb)   Gene      Family ID    Chr: Pos       rs Id         MAF_NFE   Variants                             Exonic function   Protein change
  --------------------------------------------------------------------- --------- ------------ -------------- ------------- --------- ------------------------------------ ----------------- ----------------
  *Genes with rare variants in three or more families*                                                                                                                                       
  CFH ([@ref13])                                                        *CFH*     AMD580       1:196621252    rs142266551   0         NM_000186:exon1:c.5G \> C            Non-synonymous    R2T
                                                                        *CFH*     W11-2310_2   1:196646702    ---           ---       NM_000186:exon5:c.524G \> A          Non-synonymous    R175Q
                                                                        *CFH*     W10-0408_1   1:196654311    ---           0         NM_000186:exon7:c.908G \> A          Non-synonymous    R303Q
  KMT2E/SRPK2 ([@ref8])                                                 *PUS7*    AMD930       7:105148683    rs139058270   0.006     NM_001318163:exon1:c.277 T \> C      Non-synonymous    C93R
                                                                        *PUS7*    AMD479       7:105148683    rs139058270   0.006     NM_001318163:exon1:c.277 T \> C      Non-synonymous    C93R
                                                                        *PUS7*    W08--0553    7:105148893    ---           ---       NM_001318163:exon1:c.67A \> G        Non-synonymous    S23G
  B3GALTL ([@ref7])                                                     *RXFP2*   W11--4656    13:32351535    rs121918303   0.0072    NM_001166058:exon8:c.664A \> C       Non-synonymous    T222P
                                                                        *RXFP2*   AMD580       13:32352714    rs73163317    0.0078    NM_001166058:exon9:c.779A \> G       Non-synonymous    N260S
                                                                        *RXFP2*   W07--0199    13:32367033    rs138951290   0.0014    NM_001166058:exon15:c.1522C \> G     Non-synonymous    R508G
  TMEM9/VTN ([@ref38])                                                  *PHF12*   W11-1525_1   17:27238135    rs148347485   0.0083    NM_001033561:exon10:c.2210A \> G     Non-synonymous    N737S
                                                                        *PHF12*   AMD580       17:27251125    ---           ---       NM_001033561:exon4:c.517A \> T       Non-synonymous    T173S
                                                                        *PHF12*   AMD930       17:27238135    rs148347485   0.0083    NM_001033561:exon10:c.2210A \> G     Non-synonymous    N737S
  ARMS2/HRTA1 ([@ref15])                                                *TACC2*   W09--1832    10:123844894   rs112188313   0.0068    NM_001291876:exon4:c.2879G \> A      Non-synonymous    R960K
                                                                        *TACC2*   W10-0408_1   10:123954596   ---           ---       NM_001291878:exon2:c.110C \> T       Non-synonymous    T37M
                                                                        *TACC2*   W11-1525_2   10:123844894   rs112188313   0.0068    NM_001291876:exon4:c.2879G \> A      Non-synonymous    R960K
                                                                        *TACC2*   AMD56        10:123809983   rs202197379   ---       NM_001291876:exon3:c.64G \> A        Non-synonymous    A22T
  *Genes with highest GPS[^a^](#tblfn1){ref-type="table-fn"}*                                                                                                                                
  C9 ([@ref6])                                                          *C9*      W11--4035    5:39331894     rs34882957    0.0066    NM_001737:exon5:c.499C \> T          Non-synonymous    P167S
  PRLR/SPEF2 ([@ref16])                                                 *SPEF2*   AMD930       5:35646784     rs80010329    0.0066    NM_024867:exon5:c.601A \> G          Non-synonymous    R201G
                                                                        *SPEF2*   AMD393       5:35667268     rs139580877   0.0094    NM_024867:exon9:c.1262G \> A         Non-synonymous    R421H
  CTRB2/CTRB1 ([@ref20])                                                *BCAR1*   AMD930       16:75268977    rs61743104    0.01      NM_001170721:exon4:c.1190G \> A      Non-synonymous    R397Q
                                                                        *BCAR1*   W11--4044    16:75286131    rs74024754    0.0029    NM_001170720:exon2:c.12 + 2 T \> C   Splicing          ---

^a^GPS refers to gene priority score as described in Fritsche et al. ([@ref16]), which was a scoring-based method for suggesting most likely candidate at known AMD loci based on expression, presence of rare variants and known biological function that were deemed important for AMD. Minor allele frequency (MAF) was from non-Finnish Europeans from ExAC database.

![Segregation of rare variants in genes residing within AMD-associated loci. Filled symbols represent the individuals with AMD.](ddaa057f2){#f2}

![(**A**) Mean expression of candidate genes within AMD-associated loci in human donor retina. (**B**) Heatmap showing the fold change differences observed in genes during early-, intermediate- and late-stage AMD compared to normal retina. None of the candidate reaches statistical significance of FDR ≤ 10%. (**C**) Violin plots showing the relationship between the variant and the gene of an observed eQTL. Fewer individuals with homozygous genotypes of *PUS7* (G/G) and *SPEF2* (T/T) resulted in single point in violin plots. *P*-values for the eVariants: (rs170690--3.97 **×** 10^−5^), (7:105733118--1.39 **×** 10^−5^), (rs117886541--1.12 **×** 10^−5^), (rs78996920--3.85 **×** 10^−10^), (rs12520223--1.75 **×** 10^−8^), (rs150308036--3.15 **×** 10^--7^), (rs8064132--2.04 **×** 10^−5^).](ddaa057f3){#f3}

Exome-wide analysis of rare pathogenic variants {#sec5}
-----------------------------------------------

We then extended our analysis in search of rare pathogenic variants in genes outside the GWAS loci. We selected genes with rare (MAF \< 1%) variants that were detected in at least three families and applied an additional predictive causality filter to focus on the 1% most deleterious variants in the human genome (CADD score ≥ 20). We also removed the variants that did not pass the quality score filter in Exome Aggregation Consortium (ExAC) database. Our analyses resulted in the identification of 13 candidate genes with 38 rare variants segregating in three or more families ([Table 3](#TB3){ref-type="table"}). As large or polymorphic genes harbor a large number of variants, we further prioritized the list based on the following criteria: (i) whether the gene was expressed in the human retina (CPM \> 0) and is regulated by an eQTL, (ii) whether common variants around the candidate gene exhibited a suggestive association (*P*-value \< 5 × 10^−4^) for AMD and (iii) whether the candidate gene or a closely related gene was shown to have a function relevant to AMD pathology. Ten candidate genes demonstrated expression in the human retina with a few showing changes during AMD progression ([Fig. 4](#f4){ref-type="fig"}A and B). Five of the genes also had an eQTL in the retina ([Fig. 4C](#f4){ref-type="fig"}). One candidate, *SCN10A*, showed a modest association (3:38800182_C/T; *P*-value: 9.63 × 10^−5^) in the AMD-GWAS ([Fig. 4D](#f4){ref-type="fig"}). We identified three different rare variants in *SCN10A*, one nonsense variant (Q923X) and two non-synonymous variants (P893L and P332L) in three independent AMD families ([Fig. 5A](#f5){ref-type="fig"}). A rare frameshift variant (S267fs) in *KIR2DL4* is segregated in three families ([Fig. 5B](#f5){ref-type="fig"}). Based on their role in mitochondrial biogenesis, *ESRRA* and *VPS13B*, each with rare variants in three different families, could be presented as additional interesting candidates ([Fig. 5C and D](#f5){ref-type="fig"}).

Given that segregation of rare variants in small families can be detected by chance, we performed simulation analysis to test the null case of no variant effect on disease by randomly assigning alleles to subjects in our study and then calculating the probability of observing segregation in three or more families. We applied the segregation criteria similar to the criteria that were used to identify variants in the AMD families and performed 100 000 gene-level simulations for two different variant sets: one with rare variants identified at the AMD loci and the other with exome-wide, rare variants after filtering by CADD score. We observed an average gene-level type I error rate of 7.7 **×** 10^−7^ for the AMD loci analysis and 1.87 **×** 10^−7^ for the CADD score filtered exome-wide analysis. The study-level type I error was 4.6 x 10^−4^ (AMD loci) and 2.2 **×** 10^−4^ (exome-wide). Given the pedigree structure and variants identified in our study, it is therefore unlikely to detect segregation of rare variants in three or more families by chance.

Rare variant association in case-control cohort {#sec6}
-----------------------------------------------

We further tested whether candidate genes identified in this study exhibit rare variant associations in AMD case-control studies that employed WES or whole genome sequencing (WGS) to genotype rare variants in coding regions of the genome. We analyzed the burden of rare coding variants in the eight genes within GWAS loci ([Table 2](#TB2){ref-type="table"}) and 13 genes identified in our exome-wide analysis ([Table 3](#TB3){ref-type="table"}) in two different cohorts (see Methods) ([@ref24],[@ref30]). A meta-analysis of rare variants in 3519 AMD subjects and 3754 controls suggested a burden of rare variants in the *C9* (*P* = 0.024) and *KIR2DL4* (*P* = 0.035) genes using the burden and variable threshold (VT) tests (Supplementary Material, [Table S1](#sup1){ref-type="supplementary-material"}).

Discussion {#sec7}
==========

GWAS and deep sequencing efforts have strongly supported a role for common and rare variants in AMD susceptibility. In addition to conferring high risk for AMD, rare variant studies can provide important insights into the phenotypic characteristics of the carrier patients ([@ref55],[@ref56]). The most recent GWAS examined both common and rare variants in a large cohort but was limited to the analyses of known rare variants that were present on the chip ([@ref16]) and did not allow sequencing-based discovery of rare variants. A few sequencing studies attempted to harness the power of familial cases, but their search was restricted to known AMD loci ([@ref28],[@ref49]). Here, we present the first, large-scale, genome-wide survey of rare coding variants in multiplex AMD families that identified several novel candidate genes/variants contributing to AMD susceptibility.

Within known AMD susceptibility regions, we identified rare variants at eight loci; two of these in *CFH* and *C9* have previously been reported in case-control and familial studies ([@ref18],[@ref20]). These findings further strengthen the role of the complement pathway in AMD and validate the presence of highly penetrant, functional rare variants as causal variants at these loci. Our study suggested the causal genes at other AMD loci. *PUS7* encodes a key RNA-modifying enzyme. *RXFP2* encodes a receptor for glycoprotein hormones that contains a unique low-density lipoprotein type A (LDLa) module ([@ref57]); though this gene is not expressed in the adult human retina ([@ref54]), its homolog in zebrafish is transcribed in the developing brain and retina ([@ref58]). *PHF12* encodes a member of the PHD zinc finger family of proteins involved in regulation of ribosomal biogenesis and senescence ([@ref59]) and could contribute to AMD pathology through activation of senescence. Although present in only two families, the findings of rare variants in *SPEF2* and *BCAR1* are also noteworthy as both of these candidates were highlighted as most likely candidate at the AMD-GWAS loci based on a gene priority score ([@ref16]). *SPEF2* is highly expressed in the human retina and shows a slight increase in advanced stages of AMD. SPEF2 is a cilia-related protein and its absence causes male infertility and primary ciliary dyskinesia ([@ref60]). This protein is shown to interact with IFT-related protein, IFT20 ([@ref61]) that is required for opsin trafficking and photoreceptor outer segment development ([@ref62]). *BCAR1* encodes a Src family kinase substrate that is shown to be involved in early retinal development, and a mouse model of *Bcar1* exhibits dramatic disruption of the ganglion cell layer ([@ref63]). Recently, *BCAR1* was also identified as a putative causal gene at the *CTRB2*/*CTRB1* locus by co-localization of GWAS and single-cell eQTL data ([@ref64]).

###### 

Candidates with rare coding variants (MAF \< 1%) segregating in three or more families identified in exome-wide analysis

  Gene               Chr: Pos           rs Id         No. of family    MAF_NFE                            Exonic function        Nucleotide change                  Amino acid change   CADD_phred
  ------------------ ------------------ ------------- ---------------- ---------------------------------- ---------------------- ---------------------------------- ------------------- ------------
  *CTDSP2*           chr12: 58220816    rs76940645    11               0                                  Non-synonymous         NM_005730:exon4:c.317 T \> C       I106T               25.3
  *TTN*              chr2: 179395813    rs55865284    7                0.0001                             Non-synonymous         NM_003319:exon186:c.78334G \> A    V26112M             22.1
  chr2: 179482937    rs72677232         0.0026        Non-synonymous   NM_003319:exon80:c.20053G \> A     V6685I                 21.6                                                   
  chr2: 179482994    rs72677231         0.0035        Non-synonymous   NM_003319:exon80:c.19996C \> T     R6666C                 22.2                                                   
  chr2: 179486037    rs72677225         0.0065        Non-synonymous   NM_003319:exon74:c.18213G \> T     K6071N                 22.3                                                   
  chr2: 179486223    rs17354992         0.0079        Non-synonymous   NM_003319:exon73:c.18133G \> A     D6045N                 23.2                                                   
  chr2: 179486345    rs114331773        0.0015        Non-synonymous   NM_003319:exon73:c.18011A \> T     E6004V                 22.8                                                   
  chr2: 179537200    rs202014478        0.006         Non-synonymous   NM_133378:exon149:c.30961G \> A    V10321I                21.5                                                   
  chr2: 179549407    rs72650031         0.0077        Non-synonymous   NM_133378:exon128:c.28892C \> T    P9631L                 20.1                                                   
  chr2: 179582913    rs72648981         0.003         Non-synonymous   NM_133378:exon83:c.21088G \> A     E7030K                 22.7                                                   
  chr2: 179585312    rs17452588         0.008         Non-synonymous   NM_133378:exon77:c.19445C \> T     S6482L                 22.5                                                   
  chr2: 179588622    rs201394117        0.0007        Non-synonymous   NM_133378:exon70:c.17632G \> A     A5878T                 23.6                                                   
  *KIR3DL3*          chr19: 55237616    rs143765860   4                NA                                 Non-synonymous         NM_153443:exon3:c.168C \> A        N56K                NA
  chr19: 55246731    rs602444           NA            Non-synonymous   NM_153443:exon6:c.961C \> T        H321Y                  NA                                                     
  *DCHS2*            chr4: 155156598    rs149548848   4                0.002                              Non-synonymous         NM_017639:exon25:c.7841C \> T      P2614L              24.9
  chr4: 155411721    rs199621086        0.0042        Non-synonymous   NM_001142552:exon1:c.787C \> T     R263W                  25.9                                                   
  chr4: 155411948    rs184619033        0.0074        Non-synonymous   NM_001142552:exon1:c.560G \> T     R187L                  24.2                                                   
  *DNAH14*           chr1: 225340410    rs17578819    4                0.0094                             Non-synonymous         NM_001373:exon32:c.4970G \> A      G1657E              21.8
  chr1: 225490915    rs140066130        0.0042        Non-synonymous   NM_001373:exon55:c.8410C \> T      R2804C                 34                                                     
  chr1: 225528175    rs184094753        0.0034        Stopgain         NM_001373:exon67:c.10171G \> T     E3391X                 58                                                     
  *SCN10A*           chr3: 38768123     ---           3                0                                  Stopgain               NM_001293307:exon15:c.2767C \> T   Q923X               24.9
  chr3: 38768212     rs138413438        0.0014        Non-synonymous   NM_001293307:exon15:c.2678C \> T   P893L                  24.7                                                   
  chr3: 38798606     ---                0             Non-synonymous   NM_001293306:exon8:c.995C \> T     P332L                  33                                                     
  *ESRRA*            chr11: 64083290    rs150848359   3                0.0098                             Non-synonymous         NM_001282450:exon7:c.1124G \> A    R375Q               22.4
  chr11: 64083293    rs201971362        0.0098        Non-synonymous   NM_001282450:exon7:c.1127G \> T    R376L                  22.1                                                   
  *ADPRHL1*          chr13: 114077172   rs145187729   3                0.0084                             Non-synonymous         NM_138430:exon7:c.1030G \> A       A344T               20.5
  chr13: 114107571   rs138029763        0.0076        Non-synonymous   NM_138430:exon1:c.182 T \> C       M61T                   26.2                                                   
  *KIR2DL4*          chr19: 55324674    rs11371265    3                NA                                 frameshift_insertion   NM_001080772:exon6:c.802dupA       S267fs              NA
  *PLB1*             chr2: 28805359     rs144737372   3                0.0013                             Non-synonymous         NM_001170585:exon24:c.1687A \> G   R563G               22.3
  chr2: 28854972     rs74701215         NA            Non-synonymous   NM_001170585:exon54:c.3934C \> A   P1312T                 28.1                                                   
  *TAF1C*            chr16: 84212875    rs199976567   3                0.0037                             Non-synonymous         NM_001243158:exon11:c.1286C \> T   S429L               31
  chr16: 84213651    \-                 NA            Non-synonymous   NM_001243158:exon10:c.604C \> A    Q202K                  23.3                                                   
  chr16: 84215010    \-                 0             Non-synonymous   NM_001243158:exon7:c.170G \> A     R57H                   34                                                     
  *UNC80*            chr2: 210683829    rs200473652   3                0.0019                             Non-synonymous         NM_032504:exon12:c.1806G \> C      Q602H               23.1
  chr2: 210707144    rs78912192         0.0003        Non-synonymous   NM_032504:exon21:c.3434A \> C      E1145A                 27.9                                                   
  chr2: 210860221    rs199783352        0.0005        Non-synonymous   NM_182587:exon63:c.9607G \> A      E3203K                 23.4                                                   
  *VPS13B*           chr8: 100147957    rs143205296   3                0.0005                             Non-synonymous         NM_015243:exon11:c.1559A \> G      H520R               24.8
  chr8: 100443885    rs61753722         0.0091        Non-synonymous   NM_017890:exon22:c.3203C \> T      T1068I                 24.2                                                   

![(**A**) Mean expression of the candidate genes with rare variants (MAF \< 1%) in three or more families that are located outside of AMD-associated loci. (**B**) Heatmap showing the fold change differences observed in genes during early-, intermediate- and late-stage AMD compared to normal retina. (**C**) Violin plots showing the relationship between the variant and the gene of an eQTL. Fewer individuals with homozygous genotypes of *TTN* (G/G) resulted in single point in the violin plot. *P*-values for the eVariants: (rs66773470--2.66 **×** 10^−6^), (rs2278043--5.92 **×** 10^−60^), (rs35615286--4 **×** 10^−5^), (rs58805123--2.50 **×** 10^−5^), (rs11889787--4.11 **×** 10^−5^), (rs1800792--1.56 **×** 10^−5^). (**D**) LocusZoom plot ([@ref80]) showing the association signals around *SCN10A* in most recent GWAS analysis in AMD ([@ref16]).](ddaa057f4){#f4}

![Segregation of the rare variants in *SCN10A* (**A**), *KIR2DL4* (**B**), *ESRRA* (**C**) and *VPS13B* (**D**) in AMD families.](ddaa057f5){#f5}

Our survey of candidate genes harboring rare variants outside AMD loci was aimed at identifying potential novel candidate genes underlying AMD pathology. Such candidates could have been missed in GWAS and other association studies if the gene confers the risk to AMD solely through rare variants, or if the effect size of the common risk variant is very low, warranting larger numbers of cases and controls to detect such associations. We identified 13 candidate genes that harbor rare variants in more than three families and show, by simulation studies, that the probability of these variants segregating by chance is very low. Thus, these genes represent reasonable candidates for AMD susceptibility. We propose *SCN10A* and *KIR2DL4* as the most interesting AMD candidates. Common variants at the *SCN10A* gene have been associated with AMD in a recent AMD-GWAS ([@ref16]) though not at the level of genome-wide significance, and a suggestive burden of rare variants in *KIR2DL4* has been detected in a meta-analysis of WGS data in a case-control cohort composed of 3519 cases and 3754 controls ([@ref65]). SCN10A is a voltage-gated sodium channel expressed in starburst amacrine cells and a subset of retinal ganglion cells ([@ref66]), which is likely the reason for not observing its expression in the human retina. Gain-of-function mutations in this gene cause axonal degeneration leading to painful neuropathy ([@ref67]). Several retinal diseases are caused by ion channel mutations including inherited macular degeneration ([@ref68]). *KIR2DL4*, a member of the human killer cell Ig-like receptor (KIR) family, is expressed primarily in natural killer (NK) cells and plays an important role in innate immunity ([@ref69]). NK cells interact with HLA class ligand through their KIR receptors and a certain combination of HLA-C, and KIR gene variants have been associated with AMD ([@ref70]). *ESRRA*, an estrogen-related receptor is a key regulator of energy homeostasis and mitochondrial function. *ESRRA*-null mice show altered regulation of enzymes involved in lipid, eicosanoid and steroid synthesis ([@ref71]). Dysfunction in lipid metabolism has been linked to AMD pathogenesis ([@ref72]), making *ESRRA* an attractive candidate for further investigation. *VPS13B* is a transmembrane protein with a function in vesicle-mediated transport. Mutations in this gene cause Cohen syndrome, whose clinical features include non-progressive psychomotor retardation, microcephaly and retinal dystrophy ([@ref73]).

Our study demonstrates that WES in extended families could prove valuable for identifying rare coding risk variants in potentially novel AMD genes. Similar results could be obtained from traditional case-control studies; however, that would require study designs involving much larger cohorts. A further incorporation of expression data from a large cohort of normal and AMD donors ([@ref54]) also uncovered new insights. These candidates do not reach statistical threshold (FDR ≤ 10%) in the differential expression analysis because of the clinical and genetic heterogeneity among AMD and normal individuals and limited power of the study to detect such differences. Investigation of larger cohorts as well as other AMD-relevant tissues such as RPE and choroid will be useful as additional line of evidence in validating these candidates as AMD-causing genes.

In conclusion, our family-based exome sequencing studies identified rare coding variants for novel candidate genes at eight known GWAS loci and 13 additional candidates outside GWAS regions. Further independent replications and molecular investigations of the candidate genes and variants, reported here, could provide novel mechanisms and pathways underlying AMD pathogenesis.

Materials and Methods {#sec8}
=====================

Study samples {#sec9}
-------------

The study population consisted of 264 samples from 63 multiplex AMD families is collected at two different centers. The Radboudumc cohort ([Fig. 1](#f1){ref-type="fig"}, [Table 1](#TB1){ref-type="table"}) comprised of 44 families (195 subjects). All patients gave written consent and the local ethics committees on research involving human subjects approved the study. Family ascertainment and disease classification for NEI cohort have been described in detail elsewhere ([@ref16],[@ref37]). Briefly, samples were ascertained from the clinical practice at the Kellogg Eye Center. Fundus photographs, fluorescein angiograms and eye examinations records were obtained for all probands and family members and were updated every 1--2 years. The recruitment and research protocols were reviewed and approved by the University of Michigan institutional review board, and informed consent was obtained from all study participants. Fundus findings in each eye were classified on the basis of a standardized set of diagnostic criteria established by the International Age-Related Maculopathy Epidemiological Study ([@ref74]). The Declaration of Helsinki principles was followed for all procedures. The NEI cohort ([Fig. 1](#f1){ref-type="fig"}, [Table 1](#TB1){ref-type="table"}) consisted of 19 families (69 subjects) that were collected at the University of Michigan. All patients signed informed consent, and the Institutional Review Boards of the University of Michigan and the National Eye Institute approved the study.

Whole exome sequencing {#sec10}
----------------------

Genomic DNA was extracted from the peripheral blood using standard methods. Genomic DNA samples were quantified using the Promega QuantiFluor® dsDNA system (Promega, Madison WI, USA), according to the manufacturer's instructions. The NEI families were subjected to exome sequencing using standard library preparation protocol with Agilent SureSelect Human All exon 50 Mb kit (Agilent Technologies, Santa Clara, CA), following the manufacturer's instructions ([@ref75]). Captured libraries were amplified and converted to clusters using Illumina Cluster Station, and single-end 101 bp sequencing was performed on Illumina GAIIx (Illumina, Inc., San Diego, CA). The Nimblegen SeqCap EZ Exome v2.0 44 Mb kit (Roche Nimblegen, Inc., Madison, WI) was used for performing WES in the Radboudumc families. Illumina HiSeq2000 sequencer was used to perform paired-end sequencing, using Illumina TruSeq V3 chemistry (Illumina, Inc., San Diego, CA).

Primary bioinformatics analysis {#sec11}
-------------------------------

FastQC (available at <http://www.bioinformatics.babraham.ac.uk/projects/fastqc/>) was used to confirm quality of sequencing, after which adapter indexes were removed using Trimmomatic ([@ref76]). Mapping was performed on the hg19/GRCh37 human reference genome sequence build using BWA ([@ref77]). Aligned reads were processed to mark duplicates using Picard (<http://picard.sourceforge.net>). The Genome Analysis Toolkit (GATK) recommendations for best practices were applied for variant calling, local realignment, base quality recalibration and variant recalibration ([@ref78]). The annotation of variants was performed with ANNOVAR ([@ref79]). Overlapping regions between the capture kits were identified using the mergeBed tools from the bedtools package ([@ref80]). Alternate allele frequencies of the variants in non-Finnish European (NFE) populations were obtained from the Exome Aggregation Consortium, which constituted data from 33,370 individuals.

Variant filtering and prioritization {#sec12}
------------------------------------

We removed the variants that did not pass the variant quality score recalibration (VQSR) filter. We further retained variants based on read depth (≥ 5×), and at least 20% of the reads were attributed to the alternate allele. We applied a segregation filter where we retained variants that were shared among 80% or more affected family members or segregated in all but one affected individual. Variants were discarded if they were present in one or more unaffected family members. We generated a list of rare variants with MAF \< 1% and low-frequency variants based on allele frequency data from ExAC non-Finnish Europeans ([@ref81]). The AMD locus regions were defined by the genome-wide significant variants and the variants within linkage disequilibrium (LD) (*r*^2^ \> 0.5), adding a further 500 kb to both sides, as described in the most recent AMD-GWAS analysis ([@ref16]). Finally, the variant-level data were collapsed into gene-level data by combining all variants observed in each gene across different families. For exome-wide analysis, we applied additional filters of predictive causality (CADD ≥ 20) and retained variants that passed variant quality score recalibration in the ExAC database. Common AMD-associated variants from the most recent GWAS ([@ref16]) were visualized using LocusZoom ([@ref82]).

Simulation analysis of rare variant segregation {#sec13}
-----------------------------------------------

Simulation analysis was performed to assess type I errors. We included all the variants that passed quality control, MAF and functional filters. We did not include the segregation filter in order to access the probability of genes/variants, segregating in three or more families. We started with our list of filtered variants with allele counts from the AMD loci analysis (2862 variant) and the exome-wide analysis (1299 variants) as our input. For each variant, we simulated the null case by randomly distributing its minor alleles across the 264 subjects in the study, with at most one allele per subject. Then, we applied the same segregation criteria we used in our real data analysis. Briefly, if any minor allele was assigned to a control subject, the variant was discarded; otherwise, we evaluated the segregation pattern of each family and counted properly segregating families as described above. We repeated this for all variants within each gene and then identified all segregating families. We performed 100,000 simulations for each gene in two different scenarios: ([@ref1]) 2862 variants in 600 genes within the known AMD Loci and ([@ref2]) 1299 variants with a CADD score ≥ 20 in 1176 genes exome-wide. The study-level type I error was calculated by multiplying the gene-level type I errors with the number of genes tested.

Expression and eQTL analysis of control and AMD retina {#sec14}
------------------------------------------------------

The transcriptome data of post-mortem human donor retinas from 453 donors at different stages of AMD and controls were analyzed for candidate gene prioritization. The donor retina that were graded for normal and disease status of AMD using Minnesota Grading System (MGS), with criteria similar to the Age-Related Eye Disease Study (AREDS). We analyzed 105 MGS1 (normal), 175 MGS2 (early AMD), 112 MGS3 (intermediate AMD) and 61 MGS4 (advanced AMD) after initial RNA-seq quality control described elsewhere. The mean age of donors was 80 years (range 55--107). The methods for RNA sequencing, gene expression quantitation, differential gene expression and eQTL analysis are described in detail elsewhere ([@ref54]). Briefly, RSEM expected counts from 453 samples and 18,053 genes passing the expression-level filter (≥ 1 CPM in ≥ 10% of samples) were transformed into TMM-normalized CPM and then converted into log~2~ CPM with an offset of 1. Batch effects were estimated and corrected using the supervised surrogate variable analysis (supervised sva) method within the bioconductor sva package in R. The differential expression between MGS 1 controls and each disease stage was assessed using the limma package in R. Fold changes between these comparisons were presented as heatmaps and violin plots using in-house scripts in R. The eQTL analysis included 17,389 genes and 8,924,684 genotyped and imputed common variants. The mapping of *cis*-eQTLs \[as defined by SNP-gene combination within ±1 Mb of the transcriptional start site (TSS) of each gene\] was performed using QTLtools to identify genetic variants (eVariants) that control expression of genes (eGenes) at FDR ≤ 0.05.

Rare variant association analysis in AMD case-control studies {#sec15}
-------------------------------------------------------------

We analyzed two different cohorts for this analysis. The first cohort was analyzed using whole genome sequencing data in 4787 subjects consisting of 2394 cases and 2393 controls ([@ref30],[@ref81]). All the cases had advanced AMD (GA or CNV). The second cohort was analyzed using whole exome sequencing in 1125 cases and 1361 controls ([@ref24]). RAREMETAL was used to perform the meta-analysis of gene-based tests for rare variants ([@ref83]).
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